| scholarly article | Q13442814 |
| P2093 | author name string | Edmond A Ryan | |
| Clarissa Wallace | |||
| Sharleen Imes | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Insulin Therapy | Q2002370 |
| type 2 diabetes | Q3025883 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1028-1032 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Short-term intensive insulin therapy in newly diagnosed type 2 diabetes | |
| P478 | volume | 27 |
| Q58699251 | A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes |
| Q36164723 | An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives |
| Q35879135 | Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment |
| Q36906173 | Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy |
| Q36798634 | Beta cells in type 2 diabetes - a crucial contribution to pathogenesis |
| Q36453667 | Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections |
| Q38503820 | Case Study: Remission of Type 2 Diabetes After Outpatient Basal Insulin Therapy |
| Q36428808 | Challenges and strategies for moving patients to injectable medications |
| Q51301686 | Clinical Predictors of Progressive Beta-Cell Failure in Type 2 Diabetes. |
| Q38115799 | Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes |
| Q41705110 | Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes |
| Q35305506 | Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q53592590 | Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey. |
| Q38095652 | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes |
| Q38106715 | Directed differentiation of progenitor cells towards an islet-cell phenotype |
| Q37509313 | Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated |
| Q33877687 | Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation |
| Q35853273 | Early basal insulin therapy decreases new-onset diabetes after renal transplantation. |
| Q37624279 | Early insulin treatment in type 2 diabetes: what are the pros? |
| Q33610761 | Early insulin use in type 2 diabetes: what are the cons? |
| Q37577178 | Early insulinization to prevent diabetes progression |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q46576386 | Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. |
| Q42477142 | Effect of short‐term intensive insulin therapy on quality of life in type 2 diabetes |
| Q42493971 | Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes |
| Q31144148 | Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data |
| Q37384190 | Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. |
| Q86582910 | Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes |
| Q51367108 | Effects of the modified linggui zhugan decoction (see text) combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics. |
| Q48031376 | Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period |
| Q48076623 | Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy |
| Q84805886 | Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy |
| Q37639310 | Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial |
| Q33802721 | FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling |
| Q37921903 | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? |
| Q36429827 | Glucose-responsive artificial promoter-mediated insulin gene transfer improves glucose control in diabetic mice. |
| Q48231744 | Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass |
| Q42140404 | Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission |
| Q44598061 | Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control |
| Q38065105 | Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia |
| Q42477903 | Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin |
| Q81157739 | Insulin may have a role to play in protecting beta cells from deterioration in diabetes |
| Q34585855 | Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding |
| Q37728180 | Insulin therapy stimulates lipid synthesis and improves endocrine functions of adipocytes in dietary obese C57BL/6 mice |
| Q39309680 | Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? |
| Q90161695 | Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus |
| Q34083400 | Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials |
| Q53475411 | Intensive insulin therapy in newly diagnosed type 2 diabetes. |
| Q36975546 | Intensive intravenous infusion of insulin in diabetic cats |
| Q34586302 | Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial |
| Q58717025 | Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients |
| Q37133799 | Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study |
| Q37653764 | Metabolic Stress and Compromised Identity of Pancreatic Beta Cells. |
| Q35993691 | Metabolic memory in diabetes--focus on insulin |
| Q34128192 | Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment |
| Q55447873 | Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. |
| Q42918366 | No need for the needle (at first). |
| Q35645893 | Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment |
| Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
| Q50475837 | Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes. |
| Q38951177 | Pancreatic β-cell identity in diabetes. |
| Q89475403 | Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site |
| Q90025604 | Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes |
| Q39468025 | Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q33980529 | Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation |
| Q60707245 | Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2 |
| Q37192464 | Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus |
| Q38038662 | Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q38195430 | Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis |
| Q35123342 | Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission |
| Q51364005 | Species incompatibilities in the pig-to-macaque islet xenotransplant model affect transplant outcome: a comparison with allotransplantation. |
| Q37895918 | Stem cell-based approaches for the treatment of diabetes |
| Q24186667 | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus |
| Q24202505 | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus |
| Q24236456 | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus |
| Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
| Q34102119 | The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients |
| Q51346853 | The Effect of Early Intensive Insulin Therapy on Body Fat Distribution and β-Cell Function in Newly Diagnosed Type 2 Diabetes. |
| Q37915625 | The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus |
| Q38442291 | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. |
| Q84355336 | The influence of insulin pump treatment on metabolic syndrome parameters in type 2 diabetes mellitus |
| Q37950842 | Therapeutic applications of mesenchymal stroma cells in pediatric diseases: current aspects and future perspectives |
| Q38441421 | Treating posttransplantation diabetes mellitus |
| Q37161925 | Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents |
| Q37182044 | Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling |
| Q34219402 | We can change the natural history of type 2 diabetes |
| Q47099550 | Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
| Q36047178 | β-cell function preservation after 3.5 years of intensive diabetes therapy |
Search more.